Abilify Tablets
PDF Leaflet Revision Date: 08 September 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Treatment of schizophrenia and acute manic episodes in Bipolar I Disorder.
Dosage (summary)
Starting dose 10-15 mg/day; max 30 mg/day.
Special Populations
- Elderly
- Renal impairment
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; monitor neonates for withdrawal symptoms.
Key Drug Interactions
- CYP3A4 inhibitors
- CYP2D6 inhibitors
- Valproate
- Lithium
Contraindications
- Hypersensitivity to aripiprazole
- Paediatric use under 18 years
Common side effects
- Insomnia
- Dizziness
- Nausea
- Somnolence
- Orthostatic hypotension
Counselling Points
- Avoid alcohol
- Monitor for hyperglycemia
- Caution with driving and machinery
Serious warnings
- Suicide risk
- Tardive dyskinesia
- Neuroleptic Malignant Syndrome
- Increased mortality in elderly with dementia-related psychosis
Important Disclaimer
The Abilify Tablets professional information leaflet below is the property of H Lundbeck and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
